Detail akcie Edwards Lifesci online

Business Summary: Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Edwards Lifesciences Corp revenues increased 12% to $6.07B. Net income before extraordinary items decreased 24% to $1.06B. Revenues reflect Transcatheter Aortic Valve Replacement segment increase of 9% to $4.49B, Transcatheter Mitral and Tricuspid Therapies segment increase of 56% to $550.6M, Surgical Heart Valve Therapy segment increase of 5% to $1.03B, United States segment increase of 11% to $3.54B.